idursulfase (elaprase) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW
  • Now
Idursulfase, manufactured by Takeda, is a drug used to treat Hunter syndrome. It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2320.4100 - $2900.2600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

alpha-l-iduronate sulfate sulfatase | ec 3.1.6.13 | elaprase | gsk2788723 | iduronate 2-sulfatase | iduronate-2-sulfatase | iduronate sulfatase | idursulfase | idursulfase beta | idursulfase (genetical recombination)

Organizations (57)

Research & Development (57)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Mucopolysaccharidosis II

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Mucopolysaccharidoses (Phase 4)

Mucopolysaccharidosis II ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial Organizations: 57

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue